FDA grants accelerated approval for Alzheimer’s Disease


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
FDA shows hope to Alzheimer’s Disease patients this year. The drug Aduhelm may provide a sigh of relief to the patients suffering from Alzheimer’s Disease

Alzheimer’s Disease is a neurological disease in which there is the death of the brain cells. This Alzheimer’s disease leads to memory loss and cognitive decline. This is a neurodegenerative type of disease that affects the brain. Alzheimer’s Disease was first described by Alois Alzheimer in 1906. As age advances, this problem of Alzheimer’s Disease starts stepping in. To begin with, it starts with dementia or memory loss. A slight cognitive decline that takes a steep turn towards memory loss.as we age. 

Understand the science behind Alzheimer’s Disease

Dementia is the collective name for progressive brain syndromes which affect memory, thinking, behavior, and emotion. Dementia is a leading cause of disability. Alzheimer’s Disease is the most common cause of dementia and accounts for 50-75% of all cases. This basically affects the elderly age group and can interfere with their daily activities. 

What happens in this condition of Alzheimer’s Disease?

In this condition, the brain cells and the nerves get disrupted. The transmission and the message carrying system gets affected. This transmission of nerves is responsible for memory exchange. With time, the entire brain chemistry changes and the brain shrinks. There are gaps and plaques formed between the areas of the brain. These changes affect the mental and physical condition of the body hampering physiological functions. This can hamper your ability to speak, write, understand and comprehend. It also affects your overall brain functioning. The production of certain hormones and neurotransmitters is also affected. There is a delay in all the processes of the body. 

Symptoms of Alzheimer’s Disease

Typically, Alzheimer’s Disease begins with lapses in the memory-making it difficult to find words with mood swings

Some of the symptoms are as follows: 

Forgetfulness of recent events, names, faces Difficulty in understanding what is being said  Difficulty in talking  Personality changes  Confusion sets in  Lack of mental and memory power  The decline is the ability to reason out  Stammering speech  Lack of care for themselves  Unsetting behavioral pattern  Getting up in the middle of the night to wander Mood swings with the bursting of tears  Loss of their inhibitions 

Alzheimer’s Disease is an irreversible progressive disorder that slowly takes over your brain and reduces your mental power to think. Alzheimer’s Disease may cause problems with the ability to carry out simple tasks and can affect the quality of life. The brain changes can be irreversible in some cases with the formation of amyloid plaques and the death of neurons and nerve cells. This results in the loss of neurons and their connections. 

Approval of Aduhelm

The FDA has accelerated the approval of Aduhelm, which is based on the reduction of these amyloid-beta plaques. These plaques can be quantified with the PET scan which can estimate their levels. This Aduheml is on the fast track for approval by the FDA.  The FDA is informed the company called Biogen to conduct new clinical trials to verify the drug’s clinical benefits 

With this drug by FDA, it is hoped that we can give some relief to the Alzheimer’s Disease patients and improve their quality of life 





Tags : #FDA #Alzheimersdisease #forgetfulness #dementia #FDAapproval #FDAannouncements #myhealth #medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026